Selective TYK2 Inhibition, Prenatal Cell Diagnostics, and Biomarker-Guided Immunotherapy: Expanding Precision

Mahmoud A Elkhalifa1, Robert B Kargbo2

  • 1University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States.

PubMed
Summary

Selectivity in precision medicine is advancing rapidly. Innovations in areas like TYK2 inhibitors and fetal cell diagnostics are improving treatments for neurological, oncological, and reproductive conditions.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K